2696.HK
Price:
$55.9
Market Cap:
$27.77B
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a ser...[Read more]
Industry
Biotechnology
IPO Date
2019-09-25
Stock Exchange
HKSE
Ticker
2696.HK
According to Shanghai Henlius Biotech, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 33.88. This represents a change of 165.92% compared to the average of 12.74 of the last 4 quarters.
The mean historical PE Ratio of Shanghai Henlius Biotech, Inc. over the last ten years is -19.89. The current 33.88 PE Ratio has changed -17136.82% with respect to the historical average. Over the past ten years (40 quarters), 2696.HK's PE Ratio was at its highest in in the June 2024 quarter at 14.97. The PE Ratio was at its lowest in in the March 2018 quarter at -75.81.
Average
-19.89
Median
-14.92
Minimum
-82.01
Maximum
14.74
Discovering the peaks and valleys of Shanghai Henlius Biotech, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 11.15%
Maximum Annual PE Ratio = 14.74
Minimum Annual Increase = -250.55%
Minimum Annual PE Ratio = -82.01
Year | PE Ratio | Change |
---|---|---|
2024 | 14.74 | 11.15% |
2023 | 13.27 | -250.55% |
2022 | -8.81 | -10.21% |
2021 | -9.81 | -50.98% |
2020 | -20.02 | -3.16% |
2019 | -20.67 | -54.84% |
2018 | -45.78 | -44.18% |
The current PE Ratio of Shanghai Henlius Biotech, Inc. (2696.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
6.40
5-year avg
-2.13
10-year avg
-19.89
Shanghai Henlius Biotech, Inc.’s PE Ratio is greater than CStone Pharmaceuticals (-68.32), greater than Shanghai Junshi Biosciences Co., Ltd. (-29.88), greater than Innovent Biologics, Inc. (-1288.36), greater than BeiGene, Ltd. (-112.36), greater than Ascentage Pharma Group International (-56.47),
Company | PE Ratio | Market cap |
---|---|---|
-68.32 | $7.25B | |
-29.88 | $39.25B | |
-1288.36 | $132.21B | |
-112.36 | $219.13B | |
-56.47 | $27.83B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Shanghai Henlius Biotech, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Shanghai Henlius Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Shanghai Henlius Biotech, Inc.'s PE Ratio?
How is the PE Ratio calculated for Shanghai Henlius Biotech, Inc. (2696.HK)?
What is the highest PE Ratio for Shanghai Henlius Biotech, Inc. (2696.HK)?
What is the 3-year average PE Ratio for Shanghai Henlius Biotech, Inc. (2696.HK)?
What is the 5-year average PE Ratio for Shanghai Henlius Biotech, Inc. (2696.HK)?
How does the current PE Ratio for Shanghai Henlius Biotech, Inc. (2696.HK) compare to its historical average?